Our Tenants
- AIM Therapeutics Inc.
- Ambit Biosciences
- ApoPharma Inc.
- ArcticDx Inc.
- AstraZeneca Canada Inc.
- Axela Inc.
- AXS Biomedical Animation Studio
- BioDiscovery Toronto
- BioFinance Canada
- BioQuest Innovations Inc.
- Biosign Technologies Inc.
- BML Canada Limited
- Canadian Biotechnology Education Resource Centre (CBERC)
- Cascade Therapeutics Inc.
- Cassandra Capital L.P.
- Celtic House Venture Partners
- Clera Inc.
- Constab International Inc.
- Critical Outcome Technologies Inc.
- CVCA - Canada’s Venture Capital & Private Equity Association
- Diagnostic Systems Laboratories
- GlaxoSmithKline Inc.
- htx.ca - The Health Technology Exchange
- Heenan Blaikie LLP
- The Innovations Group, University of Toronto
- iLOOKABOUT Inc.
- Innovation Institute of Ontario
- Interface Biologics
- InVisage Technologies
- In Vitro Drug Safety & BioTechnology
- Kanata Chemical Technologies
- Larial Proteomics
- MaRS Landing
- The Martin Prosperity Institute
- McLaughlin Centre for Molecular Medicine
- McLaughlin-Rotman Centre for Global Health - Program on Life Sciences, Ethics and Policy
- Merck Frosst Canada Ltd.
- NeurAxon Inc.
- NPS Pharmaceuticals
- Ontario Cancer Biomarker Network (OCBN)
- Octopz Inc.
- Ogilvy Renault LLP
- Ontario Institute for Cancer Research
- Ontario Geonomics Institute
- Ontario Innovation Trust
- Ontario Society for Excellence in Techology Transfer
- Ozmosis Research
- PricewaterhouseCoopers LLP
- RBC Royal Bank
- RBC Venture Partners
- Receptor Therapeutics Inc.
- Sigma Analysis & Management Ltd.
- Skymeter Corporation
- The Biotechnology Initiative
- Toronto Region Research Alliance
- Transition Therapeutics
- University Hospital Network Technology Development & Commercialization Office
- University Health Network
- University of Toronto Asset Management Corporation
- University of Waterloo
- Vasogen
- YYZ/Blue Sky Capital Corporation
MaRS PICKS
MaRS BLOG
- Corn Flakes: A bygone luxury of nationalism?
- Is design thinking the key to successful innovation?
- You probably have a better chance of running into Polkaroo than a female tech startup CEO